Peter C. Isakson

22.0k total citations · 7 hit papers
134 papers, 16.8k citations indexed

About

Peter C. Isakson is a scholar working on Pharmacology, Organic Chemistry and Immunology. According to data from OpenAlex, Peter C. Isakson has authored 134 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pharmacology, 33 papers in Organic Chemistry and 32 papers in Immunology. Recurrent topics in Peter C. Isakson's work include Inflammatory mediators and NSAID effects (77 papers), Eicosanoids and Hypertension Pharmacology (23 papers) and Estrogen and related hormone effects (23 papers). Peter C. Isakson is often cited by papers focused on Inflammatory mediators and NSAID effects (77 papers), Eicosanoids and Hypertension Pharmacology (23 papers) and Estrogen and related hormone effects (23 papers). Peter C. Isakson collaborates with scholars based in United States, France and Germany. Peter C. Isakson's co-authors include Karen Seibert, Jaime L. Masferrer, Scott D. Hauser, K. Leahy, James K. Gierse, Gilbert Geis, Carol M. Koboldt, Philip Needleman, Ben S. Zweifel and Walter E. Kaufmann and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Peter C. Isakson

134 papers receiving 15.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

1996 1.6k citations Ravi G. Kurumbail, Anna M. Stevens et al. Nature profile →
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

1994 1.3k citations Karen Seibert, K. Leahy et al. Proceedings of the National Academy of Sciences profile →
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

1994 1.1k citations Jaime L. Masferrer, Ben S. Zweifel et al. Proceedings of the National Academy of Sciences profile →
Pharmacological analysis of cyclooxygenase-1 in inflammation

1998 713 citations Yan Zhang, Carol M. Koboldt et al. Proceedings of the National Academy of Sciences profile →
Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis

1999 636 citations Richard C. Hubbard, Peter C. Isakson et al. profile →
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

1997 627 citations Hongmiao Sheng, Jian‐Hua Shao et al. Journal of Clinical Investigation profile →
COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.

1996 521 citations Peter C. Isakson et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter C. Isakson United States	63	9.2k	3.5k	2.8k	2.6k	2.2k	134	16.8k
Karen Seibert United States	53	11.2k 1.2×	3.9k 1.1×	3.7k 1.3×	4.5k 1.8×	2.9k 1.3×	99	18.8k
David L. DeWitt United States	59	9.1k 1.0×	4.8k 1.4×	1.5k 0.5×	3.6k 1.4×	2.9k 1.3×	109	17.4k
Jaime L. Masferrer United States	56	9.7k 1.1×	4.1k 1.1×	2.5k 0.9×	4.3k 1.7×	2.9k 1.3×	135	17.9k
Colin Funk United States	65	4.7k 0.5×	6.8k 1.9×	1.4k 0.5×	2.0k 0.8×	3.5k 1.6×	183	17.6k
Thomas E. Eling United States	67	3.5k 0.4×	5.7k 1.6×	1.4k 0.5×	1.4k 0.6×	1.9k 0.8×	294	15.0k
Philip Needleman United States	72	6.1k 0.7×	6.0k 1.7×	854 0.3×	1.7k 0.6×	4.4k 2.0×	263	20.8k
Jane A. Mitchell United Kingdom	66	5.4k 0.6×	4.6k 1.3×	950 0.3×	1.3k 0.5×	3.0k 1.4×	268	19.1k
Oliver Werz Germany	63	5.1k 0.6×	5.7k 1.6×	2.9k 1.0×	1.5k 0.6×	1.5k 0.7×	450	15.0k
William F. Stenson United States	58	3.9k 0.4×	3.4k 1.0×	564 0.2×	2.5k 1.0×	1.2k 0.6×	174	14.4k
Che‐Ming Teng Taiwan	64	2.5k 0.3×	7.6k 2.1×	3.3k 1.2×	1.7k 0.7×	1.4k 0.6×	489	16.0k

Countries citing papers authored by Peter C. Isakson

Since Specialization

Citations

This map shows the geographic impact of Peter C. Isakson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Isakson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Isakson more than expected).

Fields of papers citing papers by Peter C. Isakson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Isakson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Isakson. The network helps show where Peter C. Isakson may publish in the future.

Co-authorship network of co-authors of Peter C. Isakson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter C. Isakson. A scholar is included among the top collaborators of Peter C. Isakson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter C. Isakson. Peter C. Isakson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gierse, James K., Yan Zhang, William F. Hood, et al.. (2005). Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity. Journal of Pharmacology and Experimental Therapeutics. 312(3). 1206–1212. 72 indexed citations

Isakson, Peter C.. (2003). Pharmacology of COX-2 Inhibitors. PubMed. 37. 25–51. 3 indexed citations

Leese, Philip T., et al.. (2000). Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial. The Journal of Clinical Pharmacology. 40(2). 124–132. 294 indexed citations

Sheng, Hongmiao, Jinyi Shao, Christine A. O’Mahony, et al.. (1999). Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene. 18(4). 855–867. 54 indexed citations

Emery, Paul, H. Zeidler, Tore K Kvien, et al.. (1999). Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. The Lancet. 354(9196). 2106–2111. 410 indexed citations

Dirig, David M., Peter C. Isakson, & Tony L. Yaksh. (1998). Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. Journal of Pharmacology and Experimental Therapeutics. 285(3). 1031–1038. 177 indexed citations

Sheng, Hongmiao, Jian‐Hua Shao, Susan C. Kirkland, et al.. (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.. Journal of Clinical Investigation. 99(9). 2254–2259. 627 indexed citations breakdown →

Seibert, Karen, Yan Zhang, K. Leahy, et al.. (1997). Distribution of Cox-1 and Cox-2 in Normal and Inflamed Tissues. Advances in experimental medicine and biology. 400A. 167–170. 118 indexed citations

Kurumbail, Ravi G., Anna M. Stevens, James K. Gierse, et al.. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384(6610). 644–648. 1559 indexed citations breakdown →

10.

Masferrer, Jaime L., Peter C. Isakson, & Karen Seibert. (1996). CYCLOOXYGENASE-2 INHIBITORS. Gastroenterology Clinics of North America. 25(2). 363–372. 136 indexed citations

11.

Reitz, David B., James J. Li, Emily J. Reinhard, et al.. (1995). Novel 1,2-diarylcyclopentenes are selective, potent, and orally active cyclooxygenase inhibitors. Medicinal Chemistry Research. 5(5). 351–363. 10 indexed citations

12.

Isakson, Peter C., et al.. (1995). Discovery of a better aspirin.. PubMed. 23. 49–54. 21 indexed citations

13.

Fretland, D. J., Meire Bremer, Peter C. Isakson, et al.. (1995). Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: Impact upon Leukotriene B4- and 12(R)-HETE- mediated events. Inflammation. 19(2). 193–205. 15 indexed citations

14.

Rao, Tadimeti S., et al.. (1993). Calcium ionophore (A‐23187) induced peritoneal eicosanoid biosynthesis: a rapid method to evaluate inhibitors of arachidonic acid metabolism in vivo. Mediators of Inflammation. 2(5). 357–362. 3 indexed citations

15.

Birkeland, Marian L., et al.. (1987). T-independent and T-dependent steps in the murine B cell response to antiimmunoglobulin.. The Journal of Experimental Medicine. 166(2). 506–519. 22 indexed citations

16.

Isakson, Peter C.. (1986). Antiimmunoglobulin-treated B cells respond to a B cell differentiation factor for IgG1.. The Journal of Experimental Medicine. 164(1). 303–308. 27 indexed citations

17.

Isakson, Peter C., J W Uhr, K A Krolick, F D Finkelman, & E S Vitetta. (1980). Acquisition of cell surface IgD after in vitro culture of neoplastic B cells from the murine tumor BCL1.. The Journal of Experimental Medicine. 151(3). 749–754. 11 indexed citations

18.

Vitetta, Ellen S., Ellen Puré, Peter C. Isakson, Linda B. Buck, & Jonathan W. Uhr. (1980). The Activation of Murine B Cells: The Role of Surface Immunoglobulins. Immunological Reviews. 52(1). 211–231. 34 indexed citations

19.

Isakson, Peter C., et al.. (1977). Prostaglandins and the renin-angiotensin system in canine endotoxemia.. Journal of Pharmacology and Experimental Therapeutics. 200(3). 614–622. 15 indexed citations

20.

Needleman, Philip, et al.. (1975). Mechanism and modification of bradykinin-induced coronary vasodilation.. Proceedings of the National Academy of Sciences. 72(6). 2060–2063. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact